Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The chipmaker is the first Asian company to hit the milestone since China's PetroChina did so in 2007. A number of companies ...

Key Points Rhythm Pharmaceuticals' lone approved product currently generates minimal sales.However, recent clinical progress ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox ...

FDLO's sector-neutral approach and selective stock picking drive strong profitability and historical earnings growth. Read why FDLO ETF is a Buy.

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...